Ongoing 08 Jan 2026

DASL-HiCAP ANZUP1801

DASL-HiCAP ANZUP1801: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer

Enquire

Trial overview

Clinical Area

Radiation Oncology

Disease

Prostate

Disease site

Genitourinary (GU)

Study Phase

Phase III

Trial Identifiers

Registration number: NCT04136353

https://clinicaltrials.gov/study/NCT04136353

GenesisCare Location(s)

Newcastle (Lake Macquarie Private Hospital)

Lake Macquarie Private Hospital, 36 Pacific Highway, Gateshead, NSW, 2290, Australia

(02) 4918 4500

receptiononcologynewcastle@genesiscare.com

Find out more Get directions

Principal Investigator(s)

Radiation Oncologist

Prof Jarad Martin

MBChB BSc PhD DMed, FRANZCR GAustMS

View Profile

Clinical trials enquiries

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

First name *

Last name *

Email *

Phone *

State *

Postcode *

What is the reason for enquiry?

How would you prefer to be contacted? *

Phone

By submitting you acknowledge we will use the information you are providing to contact you about your enquiry. For more information about how we handle your personal information, please refer to the GenesisCare Privacy Policy.

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.

Disclaimer: